Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein

Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) dramatically improve progression-free survival compared to cytotoxic agents. It is therefore important to manage patients with ALK-TKIs until drug resistance occurs. Leukocytoclastic vasculitis (LCV) is a rare complication during can...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Okimoto, Tamio, Tsubata, Yukari, Hotta, Takamasa, Hamaguchi, Megumi, Okuno, Takae, Shiratsuki, Yohei, Kodama, Akari, Nakao, Mika, Amano, Yoshihiro, Hamaguchi, Shunichi, Kurimoto, Noriaki, Tobita, Reiko, Isobe, Takeshi
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2018
Ämnen:
Case Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5929456/
https://ncbi.nlm.nih.gov/pubmed/29732013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24765
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk